Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Treat to target in PsA should focus on clinical measures. Response to: 'DAPSA versus cDAPSA: do we need use CRP?' by Gonçalves et al.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC.

Ann Rheum Dis. 2019 Jul 22. pii: annrheumdis-2019-215990. doi: 10.1136/annrheumdis-2019-215990. [Epub ahead of print] No abstract available.

PMID:
31331923
2.

In Psoriatic Arthritis fatigue is driven by inflammation, disease duration, and chronic pain: An observational DANBIO registry study.

Skougaard M, Jørgensen TS, Rifbjerg-Madsen S, Coates LC, Egeberg A, Amris K, Dreyer L, Højgaard P, Guldberg-Møller J, Merola JF, Frederiksen P, Gudbergsen H, Kristensen LE.

J Rheumatol. 2019 Jul 15. pii: jrheum.181412. doi: 10.3899/jrheum.181412. [Epub ahead of print]

PMID:
31308213
3.

Should Methotrexate Have Any Place in the Treatment of Psoriatic Arthritis?

Ye W, Coates LC.

Rheum Dis Clin North Am. 2019 Aug;45(3):325-339. doi: 10.1016/j.rdc.2019.04.007. Epub 2019 May 30. Review.

PMID:
31277747
4.

Gender equity in clinical practice, research and training: Where do we stand in rheumatology?

Andreoli L, Ovseiko PV, Hassan N, Kiltz U, van Mens L, Gossec L, Coates LC.

Joint Bone Spine. 2019 Jun 17. pii: S1297-319X(19)30095-8. doi: 10.1016/j.jbspin.2019.05.005. [Epub ahead of print] No abstract available.

PMID:
31220622
5.

GRAPPA 2018 Project Report.

Goel N, FitzGerald O, Gladman DD, Helliwell PS, Kavanaugh A, Maksymowych WP, Mease PJ, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2019 Jun;95:54-57. doi: 10.3899/jrheum.190121.

PMID:
31154406
6.

Best-practice Indicators in Psoriatic Disease Care.

Helliwell PS, Favier G, Gladman DD, Soriano ER, Kirkham BW, Coates LC, Puig L, Boehncke WH, Thaçi D.

J Rheumatol Suppl. 2019 Jun;95:38-45. doi: 10.3899/jrheum.190120.

PMID:
31154403
7.

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.

Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett W.

J Rheumatol Suppl. 2019 Jun;95:33-37. doi: 10.3899/jrheum.190122.

PMID:
31154402
8.

Viable and Total Bacterial Populations Undergo Equipment- and Time-Dependent Shifts during Milk Processing.

Kable ME, Srisengfa Y, Xue Z, Coates LC, Marco ML.

Appl Environ Microbiol. 2019 Jun 17;85(13). pii: e00270-19. doi: 10.1128/AEM.00270-19. Print 2019 Jul 1.

PMID:
31028031
9.

The Role of Ultrasound in Psoriatic Arthritis - Do We Need a Score?

D'Agostino MA, Coates LC.

J Rheumatol. 2019 Apr;46(4):337-339. doi: 10.3899/jrheum.181044. No abstract available.

PMID:
30936223
10.

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity.

Coates LC, Orbai AM, Morita A, Benichou O, Kerr L, Adams DH, Shuler CL, Birt J, Helliwell PS.

BMC Rheumatol. 2018 Aug 13;2:24. doi: 10.1186/s41927-018-0030-y. eCollection 2018.

11.

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.

Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, de Wit M, Eder L, Fallon L, FitzGerald O, Gladman DD, Goel N, Holland R, Lindsay C, Maxwell L, Mease P, Orbai AM, Shea B, Strand V, Veale DJ, Tillett W, Ogdie A.

J Rheumatol. 2019 Aug;46(8):996-1005. doi: 10.3899/jrheum.181089. Epub 2019 Feb 15.

PMID:
30770518
12.

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.

Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC.

Rheumatology (Oxford). 2019 Jun 1;58(6):1025-1033. doi: 10.1093/rheumatology/key417.

13.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Duffin KC, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2019 Aug;46(8):990-995. doi: 10.3899/jrheum.181077. Epub 2018 Dec 15.

PMID:
30554154
14.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

15.

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.

Coates LC, Rahman P, Psaradellis E, Rampakakis E, Osborne B, Lehman AJ, Nantel F.

Rheumatology (Oxford). 2019 Mar 1;58(3):522-526. doi: 10.1093/rheumatology/key359.

PMID:
30517715
16.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. doi: 10.1002/acr.23789. Epub 2018 Nov 30.

PMID:
30499259
17.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.

PMID:
30499246
18.

Assessing Disease Activity in Psoriatic Arthritis: A Literature Review.

Tucker LJ, Coates LC, Helliwell PS.

Rheumatol Ther. 2019 Mar;6(1):23-32. doi: 10.1007/s40744-018-0132-4. Epub 2018 Nov 23. Review.

19.

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.

Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, de Wit M, Smolen JS, Gossec L.

Ann Rheum Dis. 2019 Feb;78(2):201-208. doi: 10.1136/annrheumdis-2018-214140. Epub 2018 Nov 15.

20.

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.

Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC.

Rheumatol Ther. 2018 Dec;5(2):567-582. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9.

21.

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.

Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E.

Arthritis Res Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0.

22.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, Abi-Saab W, Tasset C, Meuleners L, Harrison P, Besuyen R, Van der Aa A, Mozaffarian N, Greer JM, Kunder R, Van den Bosch F, Gladman DD.

Lancet. 2018 Dec 1;392(10162):2367-2377. doi: 10.1016/S0140-6736(18)32483-8. Epub 2018 Oct 22.

23.

Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity.

Ye W, Tucker LJ, Coates LC.

Drugs. 2018 Nov;78(16):1705-1715. doi: 10.1007/s40265-018-0994-3. Review.

PMID:
30341684
24.

Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.

Coates LC, Gottlieb AB, Merola JF, Boone C, Szumski A, Chhabra A.

J Rheumatol. 2019 Feb;46(2):160-165. doi: 10.3899/jrheum.180249. Epub 2018 Oct 15.

PMID:
30323006
25.

Classification and Outcome Measures for Psoriatic Arthritis.

Leung YY, Ogdie A, Orbai AM, Tillett W, Coates LC, Strand V, Mease P, Gladman DD.

Front Med (Lausanne). 2018 Sep 6;5:246. doi: 10.3389/fmed.2018.00246. eCollection 2018. Review.

26.

Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?

Tucker LJ, Ye W, Coates LC.

Curr Rheumatol Rep. 2018 Sep 18;20(11):71. doi: 10.1007/s11926-018-0781-x. Review.

27.

What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?

Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS.

J Rheumatol. 2019 Jan;46(1):38-42. doi: 10.3899/jrheum.180267. Epub 2018 Sep 15.

PMID:
30219765
28.

Personalized medicine - a new reality in psoriatic arthritis?

Al-Mossawi H, Coates LC.

Nat Rev Rheumatol. 2018 Aug;14(8):449-451. doi: 10.1038/s41584-018-0043-3. No abstract available.

PMID:
29991813
29.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19.

PMID:
29928910
30.

GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2018 Jun;94:48-51. doi: 10.3899/jrheum.180139.

PMID:
29858355
31.

Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting.

Gottlieb AB, Coates LC, van Mens LJJ, Armstrong AW, Merola JF.

J Rheumatol Suppl. 2018 Jun;94:40-43. doi: 10.3899/jrheum.180137.

PMID:
29858353
32.

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

Gladman DD, Coates LC, Jadon DR, Tillett W, Mease PJ, Vis M.

J Rheumatol Suppl. 2018 Jun;94:26-29. doi: 10.3899/jrheum.180132.

PMID:
29858349
33.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
34.

Response to: 'To DAPSA or not to DAPSA? That is not the question' by Schoels et al.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten DLP, Coates LC.

Ann Rheum Dis. 2019 Jul;78(7):e62. doi: 10.1136/annrheumdis-2018-213618. Epub 2018 May 18. No abstract available.

PMID:
29776975
35.

Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis.

Coates LC, Savage LJ, Chinoy H, Laws PM, Lovell CR, Korendowych E, Mahmood F, Mathieson HR, McGonagle D, Warren RB, Waxman R, Helliwell PS.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1530-1534. doi: 10.1111/jdv.14971. Epub 2018 May 9.

36.

Considerations for the definition of remission criteria in psoriatic arthritis.

Mease PJ, Coates LC.

Semin Arthritis Rheum. 2018 Jun;47(6):786-796. doi: 10.1016/j.semarthrit.2017.10.021. Epub 2017 Oct 31. Review.

37.

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA).

Mease PJ, Gladman DD, Samad AS, Coates LC, Liu LXH, Aras GA, Collier DH, Chung JB.

RMD Open. 2018 Feb 3;4(1):e000606. doi: 10.1136/rmdopen-2017-000606. eCollection 2018.

38.

Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.

Coates LC, Mease PJ, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-1535. doi: 10.1002/acr.23537. Epub 2018 Sep 1.

PMID:
29409133
39.

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.

Coates LC, Kishimoto M, Gottlieb A, Shuler CL, Lin CY, Lee CH, Mease PJ.

RMD Open. 2017 Dec 22;3(2):e000567. doi: 10.1136/rmdopen-2017-000567. eCollection 2017.

40.

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.

Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD.

RMD Open. 2017 Jul 18;3(1):e000415. doi: 10.1136/rmdopen-2016-000415. eCollection 2017.

41.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

42.

Current concepts and unmet needs in psoriatic arthritis.

Mahmood F, Coates LC, Helliwell PS.

Clin Rheumatol. 2018 Feb;37(2):297-305. doi: 10.1007/s10067-017-3908-y. Epub 2017 Nov 13. Review.

PMID:
29134513
43.

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1198-1205. doi: 10.1002/acr.23460. Epub 2018 Jun 28.

44.

Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC.

Ann Rheum Dis. 2018 Feb;77(2):251-257. doi: 10.1136/annrheumdis-2017-211998. Epub 2017 Oct 28.

PMID:
29080861
45.

Remission in psoriatic arthritis-where are we now?

Coates LC, Conaghan PG, D'Agostino MA, De Wit M, FitzGerald O, Kvien TK, Lories R, Mease P, Nash P, Schett G, Soriano ER, Emery P.

Rheumatology (Oxford). 2018 Aug 1;57(8):1321-1331. doi: 10.1093/rheumatology/kex344.

46.
47.

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies.

Tillett W, Orbai AM, Ogdie A, Leung YY, Strand V, Gladman DD, Mease PJ, Coates LC; GRAPPA OMERACT Psoriatic Arthritis working group.

Ann Rheum Dis. 2018 May;77(5):e23. doi: 10.1136/annrheumdis-2017-212004. Epub 2017 Jul 26. No abstract available.

PMID:
28747326
48.
49.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

50.

How routine use of a treat to target approach in PsA might impact on clinical decision making.

Coates LC.

Rheumatology (Oxford). 2018 Feb 1;57(2):209-210. doi: 10.1093/rheumatology/kex242. No abstract available.

PMID:
28666383

Supplemental Content

Loading ...
Support Center